{"id":1318,"date":"2018-09-28T16:52:02","date_gmt":"2018-09-28T14:52:02","guid":{"rendered":"http:\/\/lallianse.com\/site\/?p=1318"},"modified":"2018-09-28T16:52:02","modified_gmt":"2018-09-28T14:52:02","slug":"proteomedix","status":"publish","type":"post","link":"https:\/\/lallianse.com\/site\/proteomedix\/","title":{"rendered":"Proteomedix raises 5.2 MCHF in financing round"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb3.7.1&Prime; custom_padding=\u00a0\u00bb0|0px|0|0px|false|false\u00a0\u00bb][et_pb_row custom_padding=\u00a0\u00bb0|0px|0|0px|false|false\u00a0\u00bb _builder_version=\u00a0\u00bb3.7.1&Prime;][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb3.0.47&Prime; parallax=\u00a0\u00bboff\u00a0\u00bb parallax_method=\u00a0\u00bbon\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb3.7.1&Prime; text_font=\u00a0\u00bb||||||||\u00a0\u00bb text_orientation=\u00a0\u00bbjustified\u00a0\u00bb custom_margin=\u00a0\u00bb||10px|\u00a0\u00bb]<\/p>\n<p>ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (\u20ac 4.6 million) from existing investors.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttp:\/\/www.proteomedix.com\/main\/index.php?webcode=news_details&#038;news_id=30&#038;PHPSESSID=dhac4u4fhu2v5rlg8unegkfpb5&Prime; url_new_window=\u00a0\u00bbon\u00a0\u00bb button_text=\u00a0\u00bbRead the press release\u00a0\u00bb button_alignment=\u00a0\u00bbright\u00a0\u00bb _builder_version=\u00a0\u00bb3.7.1&Prime; custom_button=\u00a0\u00bbon\u00a0\u00bb button_text_size=\u00a0\u00bb16px\u00a0\u00bb button_font=\u00a0\u00bb||||||||\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanobiotix, a  late  clinical stage  nanomedicine  company  pioneering new approaches in the treatment of cancer, announced  today positive topline  results  of  the  Phase II\/III act.in.sarc trial  evaluating NBTXR3 in  Soft Tissue Sarcoma.<\/p>\n","protected":false},"author":1,"featured_media":585,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":""},"categories":[8],"tags":[],"jetpack_featured_media_url":"https:\/\/lallianse.com\/site\/wp-content\/uploads\/2018\/07\/nanobiotix.jpg","_links":{"self":[{"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/posts\/1318"}],"collection":[{"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/comments?post=1318"}],"version-history":[{"count":2,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/posts\/1318\/revisions"}],"predecessor-version":[{"id":1320,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/posts\/1318\/revisions\/1320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/media\/585"}],"wp:attachment":[{"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/media?parent=1318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/categories?post=1318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lallianse.com\/site\/wp-json\/wp\/v2\/tags?post=1318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}